CY1125751T1 - Συμπλοκα πρωτεϊνων-πολυμερων - Google Patents

Συμπλοκα πρωτεϊνων-πολυμερων

Info

Publication number
CY1125751T1
CY1125751T1 CY20221100538T CY221100538T CY1125751T1 CY 1125751 T1 CY1125751 T1 CY 1125751T1 CY 20221100538 T CY20221100538 T CY 20221100538T CY 221100538 T CY221100538 T CY 221100538T CY 1125751 T1 CY1125751 T1 CY 1125751T1
Authority
CY
Cyprus
Prior art keywords
protein
polymers complexes
complexes
polymers
hepatitis
Prior art date
Application number
CY20221100538T
Other languages
English (en)
Inventor
Ko-Chung Lin
Original Assignee
Pharmaessentia Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1125751(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmaessentia Corp. filed Critical Pharmaessentia Corp.
Publication of CY1125751T1 publication Critical patent/CY1125751T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στα σύμπλοκα πρωτεϊνών- πολυμερών που περιγράφονται στη περιγραφή. Επίσης περιγράφεται μια μέθοδος για τη παρασκευή ενός συμπλόκου πρωτεΐνης-πολυμερούς και η χρήση του στη θεραπεία της λοίμωξης από ιό ηπατίτιδας Β ή ιό ηπατίτιδας C.
CY20221100538T 2007-08-16 2022-08-05 Συμπλοκα πρωτεϊνων-πολυμερων CY1125751T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95627307P 2007-08-16 2007-08-16
PCT/US2008/073290 WO2009023826A1 (en) 2007-08-16 2008-08-15 Protein-polymer conjugates

Publications (1)

Publication Number Publication Date
CY1125751T1 true CY1125751T1 (el) 2023-06-09

Family

ID=40351178

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20221100538T CY1125751T1 (el) 2007-08-16 2022-08-05 Συμπλοκα πρωτεϊνων-πολυμερων
CY2022026C CY2022026I2 (el) 2007-08-16 2022-08-30 Συμπλοκα πρωτεϊνων-πολυμερων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2022026C CY2022026I2 (el) 2007-08-16 2022-08-30 Συμπλοκα πρωτεϊνων-πολυμερων

Country Status (30)

Country Link
US (1) US8143214B2 (el)
EP (2) EP4129343A1 (el)
JP (1) JP5613050B2 (el)
KR (1) KR101588465B1 (el)
CN (1) CN101367872B (el)
AR (1) AR067964A1 (el)
AU (1) AU2008286742B2 (el)
BR (1) BRPI0814482B8 (el)
CA (1) CA2696478C (el)
CL (1) CL2008002399A1 (el)
CY (2) CY1125751T1 (el)
DK (1) DK2205281T3 (el)
EA (1) EA018111B1 (el)
ES (1) ES2924727T3 (el)
FR (1) FR22C1045I2 (el)
HR (1) HRP20220937T3 (el)
HU (2) HUE059551T2 (el)
LT (1) LT2205281T (el)
MX (1) MX2010001750A (el)
MY (1) MY149148A (el)
NL (1) NL301195I2 (el)
NO (1) NO2022038I1 (el)
NZ (1) NZ583831A (el)
PL (1) PL2205281T3 (el)
PT (1) PT2205281T (el)
SI (1) SI2205281T1 (el)
TW (1) TWI381851B (el)
UA (1) UA103158C2 (el)
WO (1) WO2009023826A1 (el)
ZA (1) ZA201001777B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI421093B (zh) * 2008-07-31 2014-01-01 Pharmaessentia Corp 胜肽－聚合物綴合物
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
CN107530403A (zh) * 2014-11-06 2018-01-02 药华医药股份有限公司 用于长效型干扰素的剂量方案
CN112433048A (zh) * 2020-11-17 2021-03-02 深圳上泰生物工程有限公司 一种用于化学发光免疫法的试剂盒及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
BR0013638A (pt) * 1999-08-27 2002-05-14 Maxygen Aps Novas moléculas semelhantes a interferon beta
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
EA008505B1 (ru) * 2001-11-20 2007-06-29 Фармация Корпорейшн Конъюгаты химически модифицированного гормона роста человека
CA2473526C (en) 2002-01-18 2013-10-22 Biogen Idec Ma Inc. Polyalkylene polymer compounds and uses thereof
US7345150B2 (en) * 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
RS20050202A (en) 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
PT2644206T (pt) * 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
US7405198B2 (en) * 2003-11-24 2008-07-29 Neose Technologies, Inc. Glycopegylated erythropoietin
EA200700380A1 (ru) 2004-08-31 2007-10-26 Фармация Энд Апджон Компани Ллс Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP1869079A2 (en) * 2005-03-11 2007-12-26 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
KR101483814B1 (ko) 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
ATE548382T1 (de) 2007-09-04 2012-03-15 Biosteed Gene Expression Tech Co Ltd Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
CA2696478C (en) 2018-10-09
PL2205281T3 (pl) 2022-12-12
ES2924727T3 (es) 2022-10-10
TW200916116A (en) 2009-04-16
CN101367872B (zh) 2013-11-20
EP2205281A4 (en) 2014-10-08
ZA201001777B (en) 2010-12-29
KR20100076945A (ko) 2010-07-06
EP4129343A1 (en) 2023-02-08
BRPI0814482B1 (pt) 2021-02-02
US8143214B2 (en) 2012-03-27
KR101588465B1 (ko) 2016-01-25
MX2010001750A (es) 2010-06-01
AU2008286742A1 (en) 2009-02-19
HUS2200039I1 (hu) 2022-09-28
EA201070282A1 (ru) 2010-08-30
EP2205281B1 (en) 2022-06-29
CY2022026I1 (el) 2023-06-09
NL301195I2 (nl) 2023-03-02
CY2022026I2 (el) 2023-06-09
CL2008002399A1 (es) 2009-01-02
DK2205281T3 (da) 2022-08-15
PT2205281T (pt) 2022-08-02
NZ583831A (en) 2012-06-29
BRPI0814482A2 (pt) 2015-02-03
JP5613050B2 (ja) 2014-10-22
HUE059551T2 (hu) 2022-11-28
CA2696478A1 (en) 2009-02-19
LT2205281T (lt) 2022-09-26
WO2009023826A1 (en) 2009-02-19
JP2010536788A (ja) 2010-12-02
AU2008286742B2 (en) 2014-05-29
CN101367872A (zh) 2009-02-18
MY149148A (en) 2013-07-15
TWI381851B (zh) 2013-01-11
EA018111B1 (ru) 2013-05-30
FR22C1045I1 (fr) 2022-10-14
AR067964A1 (es) 2009-10-28
UA103158C2 (ru) 2013-09-25
BRPI0814482B8 (pt) 2021-11-23
FR22C1045I2 (fr) 2023-12-29
US20090053177A1 (en) 2009-02-26
NO2022038I1 (no) 2022-09-02
HRP20220937T3 (hr) 2022-09-30
SI2205281T1 (sl) 2022-11-30
EP2205281A1 (en) 2010-07-14
NL301195I1 (el) 2022-08-31

Similar Documents

Publication Publication Date Title
CY1125751T1 (el) Συμπλοκα πρωτεϊνων-πολυμερων
CY1119896T1 (el) Μεθοδοι για αγωγη toy hcv
CY1123324T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
CY1123152T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
CY1124742T1 (el) 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
EA201100390A1 (ru) Соединения для лечения гепатита с
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
EA200700243A1 (ru) Способы лечения гепатита с
EA200901490A1 (ru) Химические соединения
CY1113259T1 (el) Ιμιδαζολυλο διφαινυλο ιμιδαζολια ως αναστολεις ιου ηπατιτιδας c
EA201301158A1 (ru) Противовирусные соединения
EA201591220A1 (ru) Новые противовирусные агенты против инфекции вирусом гепатита в
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
EA201591702A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
GEP20146134B (en) Inhibitors of hepatitis c virus replication
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
CY1124220T1 (el) Θεραπεια της λοιμωξης του ιου της ηπατιτιδας δελτα με ιντερφερονη λαμδα
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
CY1116374T1 (el) Θεραπεια για τη λοιμωξη με τον ιο της ηπατιτιδας β μονο ή σε συνδυασμο με τον ιο της ηπατιτιδας δελτα και σχετιζομενες ασθενειες του ηπατος
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis